VIDEO: Cendakimab safe, efficacious in treating moderate-to-severe AD
Cendakimab is safe and efficacious in treating moderate-to-severe AD in adult patients.
VIDEO: Cendakimab safe, efficacious in treating moderate-to-severe AD
VIDEO: Impaired mobility in AD patients linked to sex and age
VIDEO: High sodium intake associated with increased risk of AD
VIDEO: Crisaborole efficacious long-term in treating mild-to-moderate AD
VIDEO: Topical treatment improves sleep quality in PsO, AD patients
VIDEO: Study finds link between skin disorder visibility and stigma
VIDEO: Antibiotics in first year of life linked to increased AD risk in infants
Eczema/AD linked to higher risk of eating disorders
© Chronicle Companies 2023